The Hour of the Particle - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Hour of the Particle
Is now the time for multiparticulates to shine as a controlled-release solution?


Pharmaceutical Technology
Volume 34, Issue 7, pp. 38-42

Patents on many popular medicines will soon expire, and makers of generic drugs threaten to reduce Big Pharma's profits by marketing low-cost versions of these therapies. Because the industry's pipelines remain anemic, many companies have sought to extend the patents on their products by developing new controlled-release formulations. Multiparticulate dosage forms could extend patent protection, offer great control over release rates, and expand drugmakers' formulation options.

The particulars of multiparticulates


WOOD IMAGE: AMANALIMAGESRF, GETTY IMAGES. PILLS: BALLY SCANION, DIGITAL VISION, GETTY IMAGES. SWISS CLOCK: GREGOR SCHUSTER, GETTY IMAGES. REGULAR CLOCK: STOCKBYTE, GETTY IMAGES.
Multiparticulates is a general term for roughly spherical pellets that have diameters of approximately 0.25 to 3 mm. These pellets may contain one or more active pharmaceutical ingredients (APIs), or they may consist of inert cores coated with APIs. Multiparticulates release their drug loads independently. They can be compressed into tablets, filled into hard gelatin capsules or sachets, or mixed into liquid oral suspensions.

Minitabs, one type of multiparticulate, are tablets with diameters of between 2 and 3 mm. They can be filled into hard capsules, administered as single units, or compacted into bigger tablets that release their subunits as multiple dosage forms upon disintegration.

Multiplying the means of control


Elan Drug Technologies's SODAS multiparticulate contains an active-pharmaceutical-ingredient core coated with layers of functional polymers that control the drug's release rate. (IMAGE IS COURTESY OF ELAN)
Multiparticulates can control a drug's release rate by mechanisms similar to those used in conventional controlled-release tablets. For example, a multiparticulate can release its drug load as it erodes in the gastrointestinal (GI) tract. This technique is appropriate for low-dose or low-solubility drugs. "The formulation of the particulate core can become rather sophisticated to provide a customizable release profile," says David Oakley, director of technical sales for oral dosage forms at AAIPharma (Wilmington, NC). Formulators can include permeation enhancers, buffers, or solubilizers in the pellets, for example.

But the most common approach to controlling multiparticulates' release profiles is to apply functional coatings to the pellets, says Oakley. Coatings often are selected to provide sustained or delayed release. The coating formulation can be modified to form pores through which the drug can diffuse. Manufacturers can achieve sophisticated release profiles by applying multiple coatings.

Enteric polymers such as methacrylic acid copolymer and hydroxypropyl methylcellulose phthalate protect pellets as they travel through the stomach, but dissolve in the near-neutral pH environment of the upper small intestine. Aqueous media can permeate ethyl cellulose and ammonio methacrylate copolymer coatings, thus allowing the drug to be transported from the multiparticulate, says Joe Cobb, senior formulation scientist at Metrics (Greenville, NC). Manufacturers can also coat pellets with an insoluble barrier membrane through which the drug diffuses from inside the core into the surrounding medium. Changing the coating levels or the combination of polymers that coat the multiparticulate allows the creation of complex release profiles.


An operator at Flamel Technologies empties Micropump coated multiparticulates from a fluid bed onto a tray. (IMAGE IS COURTESY OF FLAMEL TECHNOLOGIES)
The Micropump system is Flamel Technologies's (Venissieux, France) method of creating multiparticulate dosage forms. The company surrounds an inert core with an API and coats the multiparticulate with various polymers to achieve the desired controlled-release properties. The system produces multiparticulates that can be used in liquid oral suspensions. The coating that the company applies to multiparticulates withstands long-term storage in liquid suspension without any change in its permeability, says Catherine Castan, Flamel's director of research and development of oral dosage forms. Coreg CR, GlaxoSmithKline's (London) controlled-release formulation of carvedilol, uses Flamel's Micropump technology, she adds.

Although multiparticulates and tablets share similar methods for controlling drug release, multiparticulate systems offer a higher degree of flexibility in dosage-form design and development than tablets do. "Each subunit in a multiparticulate system contains part of the drug, and the sum of the drug in all subunits makes the total dose, but the functionality of the overall dose is directly correlated to the functionality of individual subunits," says Ali Rajabi-Siahboomi, senior director of scientific affairs at Colorcon (Harleysville, PA). By filling capsules with multiparticulates that release the same drug at various rates, drugmakers have the flexibility to create an array of dosage forms—from simple to complex, tailored release profiles.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here